Compare · AXSM vs ODT
AXSM vs ODT
Side-by-side comparison of Axsome Therapeutics Inc. (AXSM) and Odonate Therapeutics Inc. (ODT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. AXSM focuses on Biotechnology: Pharmaceutical Preparations, while ODT focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- AXSM is the larger of the two at $11.84B, about 274.6x ODT ($43.1M).
- AXSM has hit the wire 7 times in the past 4 weeks while ODT has been quiet.
- AXSM has more recent analyst coverage (25 ratings vs 0 for ODT).
- Company
- Axsome Therapeutics Inc.
- Odonate Therapeutics Inc.
- Price
- $229.98-2.90%
- $1.12-4.27%
- Market cap
- $11.84B
- $43.1M
- 1M return
- -8.72%
- -
- 1Y return
- +106.00%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2015
- 2017
- News (4w)
- 7
- 0
- Recent ratings
- 25
- 0
Axsome Therapeutics Inc.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. Its product pipeline includes AXS-05 for the treatment major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial for the treatment of Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. The company is also developing AXS-07 for the treatment of migraine; AXS-12 for the treatment of narcolepsy; and AXS-14 for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Odonate Therapeutics Inc.
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.
Latest AXSM
- Axsome Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy
- Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10
- Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)
- Chief Executive Officer Tabuteau Herriot exercised 49,666 shares at a strike of $4.95 and sold $11,932,256 worth of shares (49,666 units at $240.25) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Axsome Therapeutics Inc.
- Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
- Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month
- Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026
- Director Jeffs Roger sold $141,656 worth of shares (572 units at $247.65) as part of a pre-agreed trading plan, decreasing direct ownership by 0.97% to 58,367 units (SEC Form 4)
Latest ODT
- SEC Form 25-NSE filed by Odonate Therapeutics Inc.
- 60 Biggest Movers From Yesterday
- 56 Biggest Movers From Friday
- Odonate Therapeutics shares are trading lower after the company received notice from The Nasdaq Stock Market that the continued listing of its securities is no longer warranted.
- 12 Health Care Stocks Moving In Friday's Intraday Session
- Stocks That Hit 52-Week Lows On Friday
- Odonate Therapeutics Announces Expected Delisting Of Stock
- Odonate Therapeutics, Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits
- Odonate Announces Expected Delisting of Its Stock
- Stocks That Hit 52-Week Lows On Thursday